British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
Portfolio Pulse from Vandana Singh
GSK reported Q2 sales of $9.95 billion, beating analyst estimates but missing expectations in vaccine sales. The company cut its annual vaccine revenue guidance but raised its overall revenue and EPS growth forecasts for 2024. GSK's stock fell 2.44% following the announcement.
July 31, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GSK reported Q2 sales of $9.95 billion, beating analyst estimates but missing expectations in vaccine sales. The company cut its annual vaccine revenue guidance but raised its overall revenue and EPS growth forecasts for 2024. GSK's stock fell 2.44% following the announcement.
Despite beating overall sales and EPS estimates, GSK's miss in vaccine sales and the subsequent cut in annual vaccine revenue guidance negatively impacted investor sentiment, leading to a 2.44% drop in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100